Coya Therapeutics (COYA) News Today $6.03 -0.04 (-0.66%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Coya: COYA 301 – GLP-1 agonists combo synergistic in inflamation ameliorationNovember 21 at 12:36 AM | markets.businessinsider.comCoya Therapeutics files to sell 1.38M shares of common stock for holdersNovember 21 at 12:36 AM | markets.businessinsider.comHead to Head Comparison: GRI Bio (NASDAQ:GRI) vs. Coya Therapeutics (NASDAQ:COYA)November 18 at 3:08 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for COYA FY2024 Earnings?November 16, 2024 | americanbankingnews.comCoya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder Buys 1,800 SharesNovember 15, 2024 | insidertrades.comHC Wainwright Has Optimistic Outlook of COYA FY2024 EarningsCoya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Coya Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.13) per share forNovember 14, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Insider Fred Grossman Purchases 2,710 SharesNovember 13, 2024 | insidertrades.comCoya Therapeutics' (COYA) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday.November 11, 2024 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPSCoya Therapeutics (NASDAQ:COYA - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.15.November 9, 2024 | marketbeat.comCoya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial ResultsNovember 7, 2024 | finance.yahoo.comCoya Therapeutics Advances Pipeline for Neurodegenerative DiseasesNovember 7, 2024 | markets.businessinsider.comCoya Therapeutics Reports Q3 2024 Highlights and ProgressNovember 7, 2024 | markets.businessinsider.comCoya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Thursday.November 7, 2024 | marketbeat.comWeekend Warriors and Dementia; Iron Chelation and Alzheimer's; Neuro Drug Costs RiseNovember 6, 2024 | msn.comCoya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 6.3% in OctoberCoya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 186,100 shares, an increase of 6.3% from the September 30th total of 175,000 shares. Currently, 1.3% of the company's shares are sold short. Based on an average daily volume of 50,700 shares, the days-to-cover ratio is currently 3.7 days.November 1, 2024 | marketbeat.comCoya Therapeutics Announces Leadership Change and New CEONovember 1, 2024 | markets.businessinsider.comCoya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive OfficerNovember 1, 2024 | finance.yahoo.comCoya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial ResultsOctober 31, 2024 | finance.yahoo.comPromising Phase II Trial Results Support Buy Rating for Coya Therapeutics’ Alzheimer’s TreatmentOctober 31, 2024 | markets.businessinsider.comCoya Therapeutics' (COYA) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reiterated a "buy" rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday.October 30, 2024 | marketbeat.comCoya Therapeutics says Phase 2 LD-1L-2 study met primary, secondary endpointsOctober 30, 2024 | markets.businessinsider.comCoya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trialOctober 29, 2024 | reuters.comCoya Therapeutics Announces Closing of $10.0 Million Private PlacementOctober 23, 2024 | stockhouse.comCoya Therapeutics Announces $10M Private Placement to Advance PipelineOctober 22, 2024 | markets.businessinsider.comCoya Therapeutics to sell 1.379M shares at $7.25 in private placementOctober 22, 2024 | markets.businessinsider.comCoya Therapeutics Announces $10.0 Million Private PlacementOctober 22, 2024 | finance.yahoo.comCoya Therapeutics Shares Rise 9% After $10 Million Private PlacementOctober 22, 2024 | marketwatch.comExosomes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersOctober 15, 2024 | theglobeandmail.comCoya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100October 8, 2024 | finance.yahoo.comCoya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines ConferenceSeptember 24, 2024 | finance.yahoo.comResearch Analysts Issue Forecasts for Coya Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:COYA)Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Equities researchers at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for Coya Therapeutics in a note issued to investors on Monday, September 16th. HC Wainwright analyst R. Selvaraju forecasts that the company will posSeptember 19, 2024 | marketbeat.comThis Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For MondaySeptember 17, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Coya Therapeutics (COYA) with Buy RecommendationSeptember 16, 2024 | nasdaq.comCoya Reports Anti-inflammatory Effect Of COYA 302 In Inflammatory Mouse Model Of Parkinson'sSeptember 16, 2024 | markets.businessinsider.comCoya Therapeutics (NASDAQ:COYA) Stock Quotes, Forecast and News SummarySeptember 16, 2024 | benzinga.comCoya Therapeutics (NASDAQ:COYA) Now Covered by HC WainwrightHC Wainwright started coverage on Coya Therapeutics in a report on Monday. They issued a "buy" rating and a $18.00 target price on the stock.September 16, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Short Interest UpdateCoya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 160,700 shares, a decrease of 9.1% from the July 31st total of 176,700 shares. Based on an average daily trading volume, of 55,900 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.1% of the company's shares are sold short.September 3, 2024 | marketbeat.comCoya Therapeutics to Present at Upcoming Healthcare ConferencesSeptember 3, 2024 | finance.yahoo.comHere's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn SituationSeptember 3, 2024 | finance.yahoo.comCoya Therapeutics Names Arun Swaminathan Chief ExecutiveAugust 20, 2024 | marketwatch.comCoya Therapeutics Promotes Arun Swaminathan To CEOAugust 20, 2024 | markets.businessinsider.comEquities Analysts Issue Forecasts for Coya Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:COYA)Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Investment analysts at Chardan Capital raised their FY2024 earnings per share estimates for Coya Therapeutics in a report issued on Tuesday, August 13th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings of (August 16, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. lifted its stake in shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 772.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 847,490 shares of the company's stock aftAugust 16, 2024 | marketbeat.comChardan Capital Weighs in on Coya Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:COYA)Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Stock analysts at Chardan Capital issued their FY2025 earnings per share estimates for Coya Therapeutics in a report released on Tuesday, August 13th. Chardan Capital analyst K. Nakae forecasts that the company will post earnings of ($1.26) peAugust 15, 2024 | marketbeat.comCOYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024August 12, 2024 | markets.businessinsider.comCoya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial ResultsAugust 12, 2024 | finance.yahoo.comCoya Therapeutics (NASDAQ:COYA) Stock Price Down 2.9%Coya Therapeutics (NASDAQ:COYA) Trading Down 2.9%August 8, 2024 | marketbeat.comCoya reports Alzheimer's trial to present at CTAD24August 4, 2024 | investing.comCoya Therapeutics Blunders on Test ResultsAugust 2, 2024 | msn.comCoya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in MadridAugust 2, 2024 | businesswire.com Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. COYA Media Mentions By Week COYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COYA News Sentiment▼0.950.46▲Average Medical News Sentiment COYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COYA Articles This Week▼82▲COYA Articles Average Week Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Canopy Growth News Today 4D Molecular Therapeutics News Today Akebia Therapeutics News Today KalVista Pharmaceuticals News Today Alector News Today Valneva News Today Ginkgo Bioworks News Today Amylyx Pharmaceuticals News Today Q32 Bio News Today Contineum Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COYA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COYA Stock Alerts